These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28946040)

  • 21. A new twist in neuroendocrine tumor research: Pacak-Zhuang syndrome, HIF-2α as the major player in its pathogenesis and future therapeutic options.
    Jochmanova I; Lazurova I
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Jun; 158(2):175-80. PubMed ID: 24781045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VHL and HIF signalling in renal cell carcinogenesis.
    Baldewijns MM; van Vlodrop IJ; Vermeulen PB; Soetekouw PM; van Engeland M; de Bruïne AP
    J Pathol; 2010 Jun; 221(2):125-38. PubMed ID: 20225241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ARNT-dependent HIF-2 transcriptional activity is not sufficient to regulate downstream target genes in neuroblastoma.
    Persson CU; von Stedingk K; Fredlund E; Bexell D; Påhlman S; Wigerup C; Mohlin S
    Exp Cell Res; 2020 Mar; 388(2):111845. PubMed ID: 31945318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma.
    Morris MR; Hughes DJ; Tian YM; Ricketts CJ; Lau KW; Gentle D; Shuib S; Serrano-Fernandez P; Lubinski J; Wiesener MS; Pugh CW; Latif F; Ratcliffe PJ; Maher ER
    Anticancer Res; 2009 Nov; 29(11):4337-43. PubMed ID: 20032376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AN AGGRESSIVE TEMPORAL BONE SDHC PARAGANGLIOMA ASSOCIATED WITH INCREASED HIF-2α SIGNALING.
    Isaacson B; Bullova P; Frone M; Click A; Hamplova B; Rabaglia J; Woodruff S; Nwariaku F; Kathuria A; Pacak K; Ghayee HK
    Endocr Pract; 2016 Feb; 22(2):190-5. PubMed ID: 26492543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
    Blancher C; Moore JW; Robertson N; Harris AL
    Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Roles and molecular mechanisms of hypoxia-inducible factors in renal cell carcinoma].
    Zou JX; Chen K
    Yi Chuan; 2018 May; 40(5):341-356. PubMed ID: 29785943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.
    Shinojima T; Oya M; Takayanagi A; Mizuno R; Shimizu N; Murai M
    Carcinogenesis; 2007 Mar; 28(3):529-36. PubMed ID: 16920734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIF-2alpha enhances beta-catenin/TCF-driven transcription by interacting with beta-catenin.
    Choi H; Chun YS; Kim TY; Park JW
    Cancer Res; 2010 Dec; 70(24):10101-11. PubMed ID: 21159632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting HIF-2α as therapy for advanced cancers.
    Murugesan T; Rajajeyabalachandran G; Kumar S; Nagaraju S; Jegatheesan SK
    Drug Discov Today; 2018 Jul; 23(7):1444-1451. PubMed ID: 29753878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of hypoxia inducible factor-1alpha and 2alpha in genetically distinct early renal cortical tumors.
    Kim CM; Vocke C; Torres-Cabala C; Yang Y; Schmidt L; Walther M; Linehan WM
    J Urol; 2006 May; 175(5):1908-14. PubMed ID: 16600797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients.
    Emerling BM; Benes CH; Poulogiannis G; Bell EL; Courtney K; Liu H; Choo-Wing R; Bellinger G; Tsukazawa KS; Brown V; Signoretti S; Soltoff SP; Cantley LC
    Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3483-8. PubMed ID: 23378636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polycythemia and paraganglioma with a novel somatic HIF2A mutation in a male.
    Toyoda H; Hirayama J; Sugimoto Y; Uchida K; Ohishi K; Hirayama M; Komada Y
    Pediatrics; 2014 Jun; 133(6):e1787-91. PubMed ID: 24819565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.
    Ambrosetti D; Dufies M; Dadone B; Durand M; Borchiellini D; Amiel J; Pouyssegur J; Rioux-Leclercq N; Pages G; Burel-Vandenbos F; Mazure NM
    PLoS One; 2018; 13(2):e0193477. PubMed ID: 29481555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A MALAT1/HIF-2α feedback loop contributes to arsenite carcinogenesis.
    Luo F; Sun B; Li H; Xu Y; Liu Y; Liu X; Lu L; Li J; Wang Q; Wei S; Shi L; Lu X; Liu Q; Zhang A
    Oncotarget; 2016 Feb; 7(5):5769-87. PubMed ID: 26735578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two HIFs may be better than one.
    Seagroves T; Johnson RS
    Cancer Cell; 2002 Apr; 1(3):211-3. PubMed ID: 12086854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.
    Yoshino H; Nohata N; Miyamoto K; Yonemori M; Sakaguchi T; Sugita S; Itesako T; Kofuji S; Nakagawa M; Dahiya R; Enokida H
    Cancer Res; 2017 Nov; 77(22):6321-6329. PubMed ID: 28951458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of HIF-2α PAS-B domain contributes to physiological responses.
    Feng Z; Zou X; Chen Y; Wang H; Duan Y; Bruick RK
    Proc Natl Acad Sci U S A; 2018 Dec; 115(52):13240-13245. PubMed ID: 30523118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hif-2α promotes degradation of mammalian peroxisomes by selective autophagy.
    Walter KM; Schönenberger MJ; Trötzmüller M; Horn M; Elsässer HP; Moser AB; Lucas MS; Schwarz T; Gerber PA; Faust PL; Moch H; Köfeler HC; Krek W; Kovacs WJ
    Cell Metab; 2014 Nov; 20(5):882-897. PubMed ID: 25440060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.
    Fan Y; Li H; Ma X; Gao Y; Bao X; Du Q; Ma M; Liu K; Yao Y; Huang Q; Zhang Y; Zhang X
    Oncotarget; 2016 Apr; 7(14):18280-94. PubMed ID: 26943772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.